Inhibrx, Inc.

31 articles about Inhibrx, Inc.

• Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

  3/3/2022

  Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced that the U.S. Food and Drug Administration, or FDA, has granted orphan-drug designation for INBRX-101 for the treatment of alpha-1 antitrypsin deficiency, or AATD.

• Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights

  2/28/2022

  Inhibrx, Inc. reported financial results for the fourth quarter and fiscal year 2021 and provided an update on recent corporate highlights.

• Inhibrx Announces Amended Loan Agreement with Oxford

  2/22/2022

  Inhibrx, Inc., a biotechnology company with four clinical programs in development and a strong emerging pipeline, announced that it has amended its loan and security agreement with Oxford Finance LLC.

• Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data

  1/4/2022

  Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced initial results from Part 3 (combination dose escalation) of the 4-part Phase 1 trial of INBRX-106, a novel hexavalent OX40 agonist, in combination with Keytruda®, in development for the treatment of patients with solid tumors.

• Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma

  12/1/2021

  Inhibrx, Inc today announced that the U.S. Food and Drug Administration, or FDA, has granted orphan-drug designation for INBRX-109 for the treatment of chondrosarcoma.

• Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

  11/9/2021

  Inhibrx, Inc.Inhibrx, Inc., a biotechnology company with four clinical programs in development and a strong emerging pipeline, reported financial results for the third quarter of 2021 and provided an update on recent corporate highlights.

• Inhibrx Announces Presentations at SITC 2021

  11/3/2021

  Inhibrx, Inc. announced today that the Company will be presenting three poster presentations at the Society for Immunotherapy of Cancer's (SITC) annual meeting, to be held in Washington, D.C.

• Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences - Nov 01, 2021

  11/1/2021

  Inhibrx, Inc., a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced that the Company will be presenting at the Connective Tissue Oncology Society, or CTOS, 2021 Virtual Annual Meeting taking place November 10-13, 2021.

• Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors

  10/28/2021

  Inhibrx, Inc. (Nasdaq: INBX), announced the appointment of three key executives: David Matly, M.B.A., as Chief Commercial Officer; David Kao, PharmD, M.B.A., RPh, as Vice President of Regulatory Affairs; and Jack Tsai, M.D., M.B.A., as Vice President of Business Development.

• INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing

  10/12/2021

  Inhibrx, Inc. today announced interim results from a Phase 1 clinical trial evaluating the safety and pharmacokinetics of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency, or AATD.

• Inhibrx To Host Webcast Presentation of Interim Results from the Phase 1 Trial of INBRX-101, its Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

  10/11/2021

  Inhibrx, Inc. (Nasdaq: INBX), today announced that it will host a live webcast presentation on Tuesday, October 12, 2021, at 5:30 a.m. PT to provide interim results from a Phase 1 clinical trial evaluating the safety and pharmacokinetics of INBRX-101 in patients with alpha-1 antitrypsin deficiency, or AATD.